Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Halozyme Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Halozyme Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
11388 Sorrento Valley Road San Diego, CA 92121
Telephone
Telephone
858.794.8889
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow

Details:

Tecentriq (atezolizumab) is a PDL-1 inhibitor monoclonal antibody, It is approved by EMA for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC).


Lead Product(s): Atezolizumab

Therapeutic Area: Oncology Product Name: Tecentriq

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: F. Hoffmann-La Roche

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.


Lead Product(s): ACU193

Therapeutic Area: Neurology Product Name: ACU193

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Acumen Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tecentriq (atezolizumab) is a monoclonal antibody, binds with PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, drug may enable the activation of T-cells.


Lead Product(s): Atezolizumab

Therapeutic Area: Oncology Product Name: Tecentriq

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: F. Hoffmann-La Roche

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.


Lead Product(s): Efgartigimod Alfa,Hyaluronidase-qvfc

Therapeutic Area: Immunology Product Name: Vyvgart Hytrulo

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Argenx

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLANDO (testosterone undecanoate) is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando (testosterone undecanoate).


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Antares Pharma

Deal Size: $960.0 million Upfront Cash: $960.0 million

Deal Type: Acquisition May 24, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLANDO® is an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone in adult males.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Lipocine

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The combination of Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Antares Pharma

Deal Size: $960.0 million Upfront Cash: $960.0 million

Deal Type: Acquisition April 13, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLANDO ® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Product Name: Tlando

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lipocine

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Chugai represents Halozyme's twelfth global collaboration and license partner for the ENHANZE® technology. Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20).


Lead Product(s): Recombinant Human Hyaluronidase PH20 Enzyme

Therapeutic Area: Technology Product Name: rHuPH20

Highest Development Status: UndisclosedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Chugai Pharmaceutical

Deal Size: $185.0 million Upfront Cash: $25.0 million

Deal Type: Collaboration March 24, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY